Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Endokrynologia Polska
MENU
Shortcuts Submit an article Author Guidelines Polish Society of Endocrinology Reviewers 2023 Redeem voucher

open access

Vol 73, No 4 (2022)
Original paper
Submitted: 2021-11-16
Accepted: 2022-01-18
Published online: 2022-07-19
View PDF Download PDF file View HTML
Get Citation

TBX3 activating PVT1 accelerates proliferation, migration, and invasion by modulating the miR-30a/LOX axis in anaplastic thyroid carcinoma

Jing Wen12, Wei Zhang3, Yan Zhou2, Xiaoli Hu1, Lijuan Luo4, Jine Zhou4, Lixin Shi5, Shi Zhou46
DOI: 10.5603/EP.a2022.0068
·
Pubmed: 35971932
·
Endokrynol Pol 2022;73(4):690-698.
Affiliations
  1. Department of Ultrasound Centre, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China
  2. Department of Internal Medicine, Clinical Medical College, Guizhou Medical University, Guiyang, China
  3. Department of Thyroid Surgery, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China
  4. Department of Invasive Technology, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China
  5. Department of Endocrinology, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China
  6. College of Radiology Imaging, Guizhou Medical University, Guiyang, Guizhou, China

open access

Vol 73, No 4 (2022)
Original Paper
Submitted: 2021-11-16
Accepted: 2022-01-18
Published online: 2022-07-19

Abstract

Introduction: Anaplastic thyroid carcinoma (ATC) is a nearly chemo-resistant malignancy with high invasion and mortality. Long non-coding RNAs (lncRNAs) have been demonstrated to be dysregulated and play a crucial role in the development and process of ATC. The present study aimed to explore the mechanism of PVT1 dysregulation in ATC.

Material and methods: The mRNA levels of PVT1 and T-box3 (TBX3), and the protein levels of TBX3 in ATC and paracancerous tissues, and FRO and Nthy-ori 3-1 cells were determined by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) and western blot, respectively. The transcriptional factor binding site was predicted and validated between TBX3 and PVT1 promoter through the JASPAR website, and ChIP and luciferase analysis. The proliferation, migration, and invasion of FRO cells were assessed by MTT, colony formation, and transwell assays.
Results: PVT1 expression was upregulated in ATC, which was positively correlative with the level of transcription factor TBX3. Downregulation of PVT1 inhibited the proliferation, migration, and invasion of FRO cells. Moreover, TBX3 targeting the promoter region of PVT1 promoted the expression level of PVT1 and modulated the downstream signalling axis of PVT1, miR-30a/LOX. Also, interference of PVT1 reversed the stimulative role of overexpression of TBX3 in the progress of FRO cells.

Conclusion: TBX3 enhanced proliferation, migration, and invasion of ATC cells via activation of PVT1 and modulation of the miR-30a/LOX signalling axis.

Abstract

Introduction: Anaplastic thyroid carcinoma (ATC) is a nearly chemo-resistant malignancy with high invasion and mortality. Long non-coding RNAs (lncRNAs) have been demonstrated to be dysregulated and play a crucial role in the development and process of ATC. The present study aimed to explore the mechanism of PVT1 dysregulation in ATC.

Material and methods: The mRNA levels of PVT1 and T-box3 (TBX3), and the protein levels of TBX3 in ATC and paracancerous tissues, and FRO and Nthy-ori 3-1 cells were determined by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) and western blot, respectively. The transcriptional factor binding site was predicted and validated between TBX3 and PVT1 promoter through the JASPAR website, and ChIP and luciferase analysis. The proliferation, migration, and invasion of FRO cells were assessed by MTT, colony formation, and transwell assays.
Results: PVT1 expression was upregulated in ATC, which was positively correlative with the level of transcription factor TBX3. Downregulation of PVT1 inhibited the proliferation, migration, and invasion of FRO cells. Moreover, TBX3 targeting the promoter region of PVT1 promoted the expression level of PVT1 and modulated the downstream signalling axis of PVT1, miR-30a/LOX. Also, interference of PVT1 reversed the stimulative role of overexpression of TBX3 in the progress of FRO cells.

Conclusion: TBX3 enhanced proliferation, migration, and invasion of ATC cells via activation of PVT1 and modulation of the miR-30a/LOX signalling axis.

Full Text:

View PDF Download PDF file View HTML
Get Citation

Keywords

anaplastic thyroid carcinoma; PVT1; TBX3; proliferation; migration; invasion

About this article
Title

TBX3 activating PVT1 accelerates proliferation, migration, and invasion by modulating the miR-30a/LOX axis in anaplastic thyroid carcinoma

Journal

Endokrynologia Polska

Issue

Vol 73, No 4 (2022)

Article type

Original paper

Pages

690-698

Published online

2022-07-19

Page views

4037

Article views/downloads

607

DOI

10.5603/EP.a2022.0068

Pubmed

35971932

Bibliographic record

Endokrynol Pol 2022;73(4):690-698.

Keywords

anaplastic thyroid carcinoma
PVT1
TBX3
proliferation
migration
invasion

Authors

Jing Wen
Wei Zhang
Yan Zhou
Xiaoli Hu
Lijuan Luo
Jine Zhou
Lixin Shi
Shi Zhou

References (36)
  1. Siegel RL, Miller KD, Goding Sauer A, et al. Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1): 7–30.
    CrossRefPubMed
  2. Jemal A, Ward EM, Johnson CJ, et al. Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival. J Natl Cancer Inst. 2017; 109(9).
    CrossRefPubMed
  3. Abe I, Lam AKY. Anaplastic thyroid carcinoma: Updates on WHO classification, clinicopathological features and staging. Histol Histopathol. 2021; 36(3): 239–248.
    CrossRefPubMed
  4. Lin B, Ma H, Ma M, et al. The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis. Am J Transl Res . 2019; 11(19): 5888–5896.
    PubMed
  5. Janz TA, Neskey DM, Nguyen SA, et al. Is the incidence of anaplastic thyroid cancer increasing: A population based epidemiology study. World J Otorhinolaryngol Head Neck Surg. 2019; 5(1): 34–40.
    CrossRefPubMed
  6. Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2016; 17(1): 47–62.
    CrossRefPubMed
  7. Zhang H, Yu Y, Zhang K, et al. Targeted inhibition of long non-coding RNA H19 blocks anaplastic thyroid carcinoma growth and metastasis. Bioengineered. 2019; 10(1): 306–315.
    CrossRefPubMed
  8. Gou L, Zou H, Li B. Long noncoding RNA MALAT1 knockdown inhibits progression of anaplastic thyroid carcinoma by regulating miR-200a-3p/FOXA1. Cancer Biol Ther. 2019; 20(11): 1355–1365.
    CrossRefPubMed
  9. Qin AC, Qian Yi, Ma YY, et al. Long Non-coding RNA RP11-395G23.3 Acts as a Competing Endogenous RNA of miR-124-3p to Regulate ROR1 in Anaplastic Thyroid Carcinoma. Front Genet. 2021; 12: 673242.
    CrossRefPubMed
  10. Colombo T, Farina L, Macino G, et al. PVT1: a rising star among oncogenic long noncoding RNAs. Biomed Res Int. 2015; 2015: 304208.
    CrossRefPubMed
  11. Zhou Q, Chen J, Feng J, et al. Long noncoding RNA PVT1 modulates thyroid cancer cell proliferation by recruiting EZH2 and regulating thyroid-stimulating hormone receptor (TSHR). Tumour Biol. 2016; 37(3): 3105–3113.
    CrossRefPubMed
  12. Naiche LA, Harrelson Z, Kelly RG, et al. T-box genes in vertebrate development. Annu Rev Genet. 2005; 39: 219–239.
    CrossRefPubMed
  13. Perkhofer L, Walter K, Costa IG, et al. Tbx3 fosters pancreatic cancer growth by increased angiogenesis and activin/nodal-dependent induction of stemness. Stem Cell Res. 2016; 17(2): 367–378.
    CrossRefPubMed
  14. Krstic M, Kolendowski B, Cecchini MJ, et al. TBX3 promotes progression of pre-invasive breast cancer cells by inducing EMT and directly up-regulating SLUG. J Pathol. 2019; 248(2): 191–203.
    CrossRefPubMed
  15. Boyd SC, Mijatov B, Pupo GM, et al. Oncogenic B-RAF(V600E) signaling induces the T-Box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion. J Invest Dermatol. 2013; 133(5): 1269–1277.
    CrossRefPubMed
  16. Li X, Ruan X, Zhang P, et al. TBX3 promotes proliferation of papillary thyroid carcinoma cells through facilitating PRC2-mediated p57 repression. Oncogene. 2018; 37(21): 2773–2792.
    CrossRefPubMed
  17. Kumar P P, Emechebe U, Smith R, et al. Coordinated control of senescence by lncRNA and a novel T-box3 co-repressor complex. Elife. 2014; 3.
    CrossRefPubMed
  18. Saini S, Tulla K, Maker AV, et al. Therapeutic advances in anaplastic thyroid cancer: a current perspective. Mol Cancer. 2018; 17(1): 154.
    CrossRefPubMed
  19. Taniue K, Akimitsu N. The Functions and Unique Features of LncRNAs in Cancer Development and Tumorigenesis. Int J Mol Sci. 2021; 22(2).
    CrossRefPubMed
  20. Samimi H, Sajjadi-Jazi SM, Seifirad S, et al. Molecular mechanisms of long non-coding RNAs in anaplastic thyroid cancer: a systematic review. Cancer Cell Int. 2020; 20: 352.
    CrossRefPubMed
  21. Shang AQ, Wang WW, Yang YB, et al. Knockdown of long noncoding RNA PVT1 suppresses cell proliferation and invasion of colorectal cancer via upregulation of microRNA-214-3p. Am J Physiol Gastrointest Liver Physiol. 2019; 317(2): G222–G232.
    CrossRefPubMed
  22. Shen SN, Li Ke, Liu Y, et al. Down-regulation of long noncoding RNA PVT1 inhibits esophageal carcinoma cell migration and invasion and promotes cell apoptosis via microRNA-145-mediated inhibition of FSCN1. Mol Oncol. 2019; 13(12): 2554–2573.
    CrossRefPubMed
  23. Zheng X, Zhao K, Liu T, et al. Long noncoding RNA PVT1 promotes laryngeal squamous cell carcinoma development by acting as a molecular sponge to regulate miR-519d-3p. J Cell Biochem. 2019; 120(3): 3911–3921.
    CrossRefPubMed
  24. Feng K, Liu Yu, Xu LJ, et al. Long noncoding RNA PVT1 enhances the viability and invasion of papillary thyroid carcinoma cells by functioning as ceRNA of microRNA-30a through mediating expression of insulin like growth factor 1 receptor. Biomed Pharmacother. 2018; 104: 686–698.
    CrossRefPubMed
  25. Lin QY, Qi QL, Hou S, et al. LncRNA PVT1 Acts as a Tumor Promoter in Thyroid Cancer and Promotes Tumor Progression by Mediating miR-423-5p-PAK3. Cancer Manag Res. 2020; 12: 13403–13413.
    CrossRefPubMed
  26. Wang J, Gu J, You A, et al. The transcription factor USF1 promotes glioma cell invasion and migration by activating lncRNA HAS2-AS1. Biosci Rep. 2020; 40(8).
    CrossRefPubMed
  27. Zhang L, Wang H, Xu M, et al. Long noncoding RNA HAS2-AS1 promotes tumor progression in glioblastoma via functioning as a competing endogenous RNA. J Cell Biochem. 2020; 121(1): 661–671.
    CrossRefPubMed
  28. Yang X, Qi F, Wei S, et al. The Transcription Factor C/EBPβ Promotes HFL-1 Cell Migration, Proliferation, and Inflammation by Activating lncRNA HAS2-AS1 in Hypoxia. Front Cell Dev Biol. 2021; 9: 651913.
    CrossRefPubMed
  29. Wang Y, Zhou J, Wang Z, et al. Upregulation of SOX2 activated LncRNA PVT1 expression promotes breast cancer cell growth and invasion. Biochem Biophys Res Commun. 2017; 493(1): 429–436.
    CrossRefPubMed
  30. Aliwaini S, Lubbad AM, Shourfa A, et al. Overexpression of TBX3 transcription factor as a potential diagnostic marker for breast cancer. Mol Clin Oncol. 2019; 10(1): 105–112.
    CrossRefPubMed
  31. Miao ZF, Liu XY, Xu HM, et al. Tbx3 overexpression in human gastric cancer is correlated with advanced tumor stage and nodal status and promotes cancer cell growth and invasion. Virchows Arch. 2016; 469(5): 505–513.
    CrossRefPubMed
  32. Huang Y, Zhu H, Ji X, et al. TBX3 knockdown suppresses the proliferation of hypopharyngeal carcinoma FaDu cells by inducing G1/S cell cycle arrest and apoptosis. Oncol Lett. 2020; 19(1): 113–120.
    CrossRefPubMed
  33. Chan JJ, Tay Y. Noncoding RNA:RNA Regulatory Networks in Cancer. Int J Mol Sci. 2018; 19(5).
    CrossRefPubMed
  34. Wang L, Xiao B, Yu T, et al. lncRNA PVT1 promotes the migration of gastric cancer by functioning as ceRNA of miR-30a and regulating Snail. J Cell Physiol. 2021; 236(1): 536–548.
    CrossRefPubMed
  35. Muther C, Jobeili L, Garion M, et al. An expression screen for aged-dependent microRNAs identifies miR-30a as a key regulator of aging features in human epidermis. Aging (Albany NY). 2017; 9(11): 2376–2396.
    CrossRefPubMed
  36. Yu Y, Shi E, Gu T, et al. Overexpression of microRNA-30a contributes to the development of aortic dissection by targeting lysyl oxidase. J Thorac Cardiovasc Surg. 2017; 154(6): 1862–1869.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl